Triclabendazole progress report, 2005-2009: an advancement of learning?
about
Activity of OZ78 analogues against Fasciola hepatica and Echinostoma caproniEfficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trialsFascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla State, Mexico: epidemiology and treatment with nitazoxanideTriclabendazole sulfoxide causes stage-dependent embryolethality in zebrafish and mouse in vitroA transmission electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica.Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukesSystems parasitology: effects of Fasciola hepatica on the neurochemical profile in the rat brain.Biochemical characterization and differential expression of a 16.5-kilodalton tegument-associated antigen from the liver fluke Fasciola hepatica.In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78The activity of dispiro peroxides against Fasciola hepatica.Gene Expression Profile in the Liver of BALB/c Mice Infected with Fasciola hepatica.The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2/BCRPFasciola hepatica: Histology of the Reproductive Organs and Differential Effects of Triclabendazole on Drug-Sensitive and Drug-Resistant Fluke Isolates and on Flukes from Selected Field CasesImmune response of rats vaccinated orally with various plant-expressed recombinant cysteine proteinase constructs when challenged with Fasciola hepatica metacercariae.A deep exploration of the transcriptome and "excretory/secretory" proteome of adult Fascioloides magna.In vitro and in vivo trematode models for chemotherapeutic studies.Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control.In vitro ovicidal activity of Peganum harmala seeds extract on the eggs of Fasciola hepatica.A mucin-like peptide from Fasciola hepatica induces parasite-specific Th1-type cell immunity.Ultrastructural changes to the tegumental system and gastrodermal cells of adult Fasciola hepatica following treatment in vivo with a commercial preparation of myrrh (Mirazid).Ovicidal effect of the methanolic extract of ginger (Zingiber officinale) on Fasciola hepatica eggs: an in vitro study.Efficacy of a single oral dose of oxfendazole against Fasciola hepatica in naturally infected sheep5-Chloro-2-methyl-sulfanyl-6-(naphtha-len-1-yl-oxy)-1H-benzimidazole methanol monosolvate.Fasciola and fasciolosis in ruminants in Europe: Identifying research needs.Confirmation of Fasciola hepatica resistant to triclabendazole in naturally infected Australian beef and dairy cattle.Electron microscopical study to assess the in vitro effects of the synthetic trioxolane OZ78 against the liver fluke, Fasciola hepatica.The anti-fasciolasis properties of silver nanoparticles produced by Trichoderma harzianum and their improvement of the anti-fasciolasis drug triclabendazole.Inhibition of cytochrome P450-mediated metabolism enhances ex vivo susceptibility of Fasciola hepatica to triclabendazole.FhCaBP4: a Fasciola hepatica calcium-binding protein with EF-hand and dynein light chain domains.Structural insights into natural compounds as inhibitors of Fasciola gigantica thioredoxin glutathione reductase.Development of Experimental Vaccines Against Liver Flukes.Fasciola hepatica induces Foxp3 T cell, proinflammatory and regulatory cytokine overexpression in liver from infected sheep during early stages of infection.Harnessing Genomic Technologies to Explore the Molecular Biology of Liver Flukes-Major Implications for Fundamental and Applied Research
P2860
Q24630199-5A355820-2D5C-410F-9BAA-286DC38136BCQ28476800-92AAB2AB-895A-43C9-94B7-A52F184CBBC6Q28535341-EF110E6F-4433-4F95-B102-9F7BB0C4998EQ28544746-ED529DB9-ECC4-4F51-8BDF-2BFAE625B231Q33520555-C5FF96AE-5C9F-4CB2-AB26-9462E04B7206Q33529290-04243357-B1F7-42E9-B128-6BE7FE552ED9Q34078891-F34852C5-E964-424A-B6FF-25828384F03DQ34141229-B3EF41FA-9130-4EA9-8E3A-F1C6DDC88525Q34290075-51167984-9471-4331-802C-309EFC349F1AQ35175961-48896916-F43C-413D-8988-CD5941772585Q35738760-161977CF-74E3-4229-90E7-CCA6EDE86948Q36086400-A57602DE-5078-449C-A19B-6C92D7C2A47EQ36096359-7B2BF270-1A08-4121-B774-F75136449F3DQ36319768-2E168730-383B-4017-BD89-6093749E3DBEQ36386873-EAB91E72-02D2-4C14-B44D-0CD946B9DB9EQ37644571-27BDF021-4AF8-4E30-BCAC-B77B92083EC0Q37846890-78DDEB81-CB09-4070-887B-418AE0F39EB5Q40171999-2DC3B933-E487-4D48-8F8B-B7EA2FA062A5Q40242084-8BDFB042-F261-41D1-9AD5-45B38EC20A21Q40497193-2700FF67-B9AC-47B0-ADD3-0781A6F564CBQ40548137-69CC16B9-9906-48A7-98FA-2D37E488E0C2Q41436763-F8197C73-A9D6-4CA3-A03D-2A85604CEC2FQ41914756-E85319F5-949D-4D70-AE87-9AFB060C4DFBQ41922974-38BC33C2-77DF-4501-9292-427AA26B2AE1Q41991869-8CFD79EA-49F0-449D-8456-BAC4B7AA18B0Q42458074-E143AD39-9B4B-473B-8896-FCD1291B47C9Q42836061-4F50C9DA-C80B-4778-85E8-B53DCAA0B427Q43212883-4C75DD05-02AC-4A2F-A7ED-29BB7534945DQ43458659-E6BE63CD-714E-4BA1-B2D2-23FDAF35B76FQ46279646-8B5D8E45-683E-43C4-AFF5-AE4D95CB73BEQ51372258-8F54FE11-1BB5-40A6-8D63-4D565B2C0FD8Q55518011-30BCF941-F976-415B-A862-410EDBB05F3DQ56984609-00B58BDD-312D-4C07-BC22-ED619BCCA408
P2860
Triclabendazole progress report, 2005-2009: an advancement of learning?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Triclabendazole progress report, 2005-2009: an advancement of learning?
@en
Triclabendazole progress report, 2005-2009: an advancement of learning?
@nl
type
label
Triclabendazole progress report, 2005-2009: an advancement of learning?
@en
Triclabendazole progress report, 2005-2009: an advancement of learning?
@nl
prefLabel
Triclabendazole progress report, 2005-2009: an advancement of learning?
@en
Triclabendazole progress report, 2005-2009: an advancement of learning?
@nl
P2860
P1476
Triclabendazole progress report, 2005-2009: an advancement of learning?
@en
P2093
I Fairweather
P2860
P304
P356
10.1017/S0022149X09321173
P577
2009-04-15T00:00:00Z